Navigation Links
Global Coronary Stents Industry
Date:12/8/2011

Metal and Drug Eluting Stent Markets

Independently Analyzed with Annual Sales in Thousand Units

for years 2003 through 2008 (includes corresponding

Graph/Chart) 147

Table 93: Russian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Dollar Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 148

Table 94: Russian 15-Year Perspective for Coronary Stents by

Product Segment - Percentage Breakdown of Unit Sales for

Bare Metal Stents and Drug Eluting Stents Markets for years

2003, 2010 & 2017 (includes corresponding Graph/Chart) 149

15g. REST OF EUROPE 150

Market Analysis 150

Table 95: Rest of Europe Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in US$ Million for years 2009 through 2017

(includes corresponding Graph/Chart) 150

Table 96: Rest of Europe Recent Past, Current & Future

Analysis for Coronary Stents by Product Segment - Bare Metal

Stent and Drug Eluting Stent Markets Independently Analyzed

with Annual Sales in Thousand Units for years 2009 through

2017 (includes corresponding Graph/Chart) 151

Table 97: Rest of Europe Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in US$

Million for years 2003 through 2008 (includes corresponding

Graph/Chart) 152

Table 98: Rest of Europe Historic Review for Coronary Stents

by Product Segment - Bare Metal and Drug Eluting Stent

Markets Independently Analyzed with Annual Sales in Thousand

Units for years 2003 through 2008 (includes corresponding

Graph/Chart) 153


'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Armada Health Care (Armada), the ... is pleased to announce an agreement with Aurora ... of innovative specialty pharmacy patient program offerings. The ... management services to specialty patients via Armada,s proprietary ... Aurora will use the OTM platform as its ...
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 Professional Compounding ... paediatric medicine by awarding the three best scientific ... initiative (EuPFI) conference . The Formulating Better ... 18 in Athens, Greece , ... students and professionals, from which three winners will ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
(Date:8/21/2014)... Black mothers are less likely than white moms to ... Hospitals in neighborhoods with many black residents do less ... white residents, a U.S. government study finds. Key ... medical centers where the black population is higher than ... and Prevention reported Thursday. These practices include efforts ...
(Date:8/21/2014)... 21, 2014 The W. Montague ... and a national voice in the elimination of ... disparities during the 112th National Medical Association’s (NMA) ... included: , John Ruffin, Ph.D, former Director of ... Disparities, whose life-long career and innovations have had ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... Reporter , MONDAY, Oct. 11 (HealthDay News) -- People with ... if they don,t have full-blown diabetes, a new study indicates. ... insulin resistance -- a reduction in the ability of the ... be helpful in preventing stroke, the researchers noted. Treating ...
... Osteoporosis Canada aimed at preventing fragility fractures in ... are published in CMAJ ( Canadian Medical Association ... "Fragility fractures, the consequence of osteoporosis, are ... and economic costs," writes Dr. Alexandra Papaioannou, McMaster ...
... the last six months of life has become progressively more ... in the United States and older adults in Canada, with ... of life in both countries, according to two reports posted ... print issue of Archives of Internal Medicine , one ...
... with blockages in the carotid artery that supplies blood ... appears to be associated with an increased risk of ... surgical treatment (carotid endarterectomy), according to a meta-analysis of ... will appear in the February 2011 print issue of ...
... treatment for retinal conditions nearly doubled between 1997 and ... most commonly performed, according to a report in the ... of the JAMA/Archives journals. "Retinal disease is highly ... (AMD) and diabetic retinopathy account for more than half ...
... the standard treatment for ovarian cancer, does not improve ... according to a study published online October 11 in ... Cisplatin plus paclitaxel, and carboplatin plus paclitaxel, are ... ovarian cancer. Still, most women relapse and die from ...
Cached Medicine News:Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 3Health News:Treatment of retinal conditions appears to have changed significantly in previous decade 2Health News:Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival 2Health News:Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival 3
... DXC-990 camera is a 3 chip 1/2 inch color ... and a high s/n ratio. It offers picture contrast ... and knee control. The user can choose automatic exposure ... The Sony DXC-990 camera is a bayonet mount and ...
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
... image management. Mediscan is an advanced ... derived from extensive experience with clinicians. ... organize, and distribute high quality images, ... effort. Can be connected to flexible ...
For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
Medicine Products: